Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD
SHANGHAI,Jan. 18,2023 -- Abbisko Therapeutics Co.,Ltd. ("Abbisko Therapeutics" hereafter)today announced that its CSF-1R inhibitor,pimicotinib (ABSK021),has been approved by the National Medical Products Administration ("NMPA") of the People's Republicof China for a phase IIclinical study in patients with chronic graft-versus-host disease ("cGVHD"). Pre-clinical data indicated that pimicotinib is a highly potent and selective small molecule inhibitor of CSF-1R that may play important roles for treating many human diseases including complications associated with transplantations.
There is a huge unmet clinical need and commercial value for CSF-1R inhibitors against chronic graft-versus-host disease worldwide. It is understood that in September 2021,Syndax and Incyte agreed to jointly develop and commercialize Syndax's anti-CSF-1R monoclonal antibody axatilimab for treating chronic graft-versus-host disease and other fibrotic diseases. Under the agreement,Syndax can receive up to $117 million upfront,an equity investment of $35 million,and up to $450 million in potential milestone payments. Compared with antibody drugs,small molecule CSF-1R inhibition has possible safety,compliance,and production cost advantages.
Pimicotinib is a novel,orally available,highly selective,and highly potent small molecule inhibitor of CSF-1R,independently discovered and developed by Abbisko Therapeutics. A number of studies have shown that blocking the CSF-1R signaling pathway could effectively modulate and change macrophage functions,and potentially treat many macrophage-dependent human diseases. Pimicotinib is currently being investigated as a treatment for tenosynovial giant cell tumor (TGCT) and cGVHD,and under evaluation as treatment for a number of other indications.
In July 2022,pimicotinib was granted Breakthrough Therapy Designation from the Center for Drug Evaluation,NMPA for the treatment of TGCT that is not amenable to surgery. Subsequently in October 2022,Abbisko Therapeutics obtained CDE approval to conduct a Phase III clinical trial in TGCT for pimicotinib. Prior to these,pimicotinib demonstrated significant antitumor efficacy in a phase Ib trial in patients with TGCT,achieving a preliminary ORR of 68.0% and favorable safety profile.
Abbisko Therapeutics also completed a Phase Ia dose escalation study for ABSK021 in the U.S. and is conducting an ongoing Phase Ib multi-cohort expansiontrial in both the U.S. and China. In addition toTGCT and cGVHD,Abbisko Therapeutics is actively exploring the potential of ABSK021 in treatingmany other types of solid tumors and has collaborated with Sperogenix (Shanghai) MedTechCo.,Ltd. in exploring its potential for treating amyotrophic lateral sclerosis (ALS) among other centralnervous system disorders. As of current,no highly selective CSF-1R inhibitorhas been approved in China.
About cGVHD
Chronic graft-versus-host disease (cGVHD) is the clinicopathological syndrome (including classical cGVHD and overlap syndrome) caused by donor lymphocytes attacking the recipient organs during the process of rebuilding recipient immunity after allogeneic hematopoietic stem cell transplantation,which is one of the major complications after transplantation. According to Chinese consensus on the diagnosis and management of cGVHD (2021),the incidence ranges from 30 to 70%.
The clinical manifestations of cGVHD are diverse with great individual differences,and the course of cGVHD is long-lasting. Multiple vital organs can become involved,thereby seriously affecting the quality of life and long-term survival of patients. Glucocorticoids are still the standard first-line treatment for cGVHD but more than half of treated patients will develop resistance and require second-line therapy. There are currently no approved therapeutic agents for patients with cGVHD who have failed to respond to glucocorticoid therapy in China.
The main pathophysiological process of cGVHD is immune inflammation,and the common characteristic pathological changes are chronic tissue repair and fibrosis. In this process,macrophage activation dependent on colony stimulating factor (CSF-1) promotes inflammatory response and tissue damage,and accelerates abnormal tissue repair and fibrosis,leading to the manifestations of cGVHD.
About AbbiskoTherapeutics
Abbisko Therapeutics (StockCode:02256) is an oncology-focused biopharmaceutical companyfounded in Shanghai,dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding,Abbisko Therapeutics has built an extensive pipeline of 15 innovative small molecule programs focused on precision oncology and immuno-oncology,and received 16 IND or clinical trial approvals in multiple countries and regions.
Please visit www.abbisko.com for more information.
